Study: NCT02308527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: 10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: 10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: OTHER
Intervention: Dinutuximab Beta
Description: 10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression